Movers and SHAKERS
Wednesday, May 8, 2019
Small Piece of Migraine Market Could be a Big Deal.
electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Market Opportunity. Upon establishment of reimbursement coverage, we expect to see a ramp up in revenue and further adoption in the market in H219. We believe potential approval in prevention of migraine and acute migraine treatment in adolescents to be a potential value generator, and the migraine indication to be the dominant market for electroCore.
- Protraction in Commercialization. electroCore is engaging in multiple key aspects to foster commercialization by expanding the sales force, reimbursement coverage, as well as promotional and educational programs. We believe electroCor...
Get full report on Channelchek desktop.
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.